Skip to content

Sanofi AEOLUS - Chronic Obstructive Pulmonary Disease (COPD) Study

Chronic Obstructive Pulmonary Disease (COPD) | COPD Research | COPD Symptoms and Signs | Pulmonary...

The purpose of this clinical research is to look at whether dupilumab works and how safe it is in adults with Chronic Obstructive Pulmonary Disease (COPD).

If you choose and are eligible to take part, you will be in the study for a minimum of 26 weeks and up to 40 weeks.

The study will consist of 3 parts:
1. Screening Period: 3 weeks period
2. Treatment Period: 24 weeks period
3. Follow-up period: 12 weeks follow-up period

null

Participation Requirements

  • Sex:

    Male, Female, Intersex

  • Eligible Ages:

    40 to 85

Participation Criteria

Inclusion Criteria:
You might be eligible to participate in this study if:
1) You are 40 to 85 years of age,
2) You have Chronic Obstructive Pulmonary Disease (COPD).
Exclusion Criteria:
You may not be eligible to participate in this study if:
1) You do not have Chronic Obstructive Pulmonary Disease (COPD).
2) Under the age of 40 or over the age of 85,
3) You are pregnant or breastfeeding.

Study Location

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: REB25-1198